Shanghai Bio-heart Biological Technology (HKG:2185) subsidiary Zhejiang Bioheart Medical Equipment will receive a 155.6 million yuan capital injection from Jiaxing Guojian Baixin Equity Investment Partnership Enterprise in exchange for a 45.3208% stake in Zhejiang Bioheart.
Upon completion of the capital increase, Shanghai Bio-heart's stake in Zhejiang Bioheart will be reduced to 54.6792%, with Jiaxing Guojian Baixin Equity Investment Partnership Enterprise holding the remainder.
Price (HKD): $1.64, Change: $-0.050, Percent Change: -2.96%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。